CNF 201

Drug Profile

CNF 201

Alternative Names: CNF201

Latest Information Update: 08 Apr 2010

Price : $50

At a glance

  • Originator Biogen Idec
  • Class Antineoplastics
  • Mechanism of Action ERBB 2 receptor antagonists; Heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 08 Apr 2010 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
  • 03 May 2006 Conforma Therapeutics has been acquired and merged into Biogen Idec
  • 21 Dec 2001 Preclinical development for Breast cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top